Huntington National Bank lowered its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 11.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,106 shares of the medical instruments supplier’s stock after selling 5,646 shares during the period. Huntington National Bank’s holdings in Becton Dickinson and were worth $10,793,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Verus Capital Partners LLC purchased a new stake in shares of Becton Dickinson and during the fourth quarter worth $27,000. Solstein Capital LLC purchased a new stake in shares of Becton Dickinson and in the first quarter worth $27,000. Watson Rebecca purchased a new stake in shares of Becton Dickinson and in the second quarter worth $36,000. Campbell Wealth Management purchased a new stake in shares of Becton Dickinson and in the second quarter worth $42,000. Finally, Harwood Advisory Group LLC purchased a new stake in shares of Becton Dickinson and in the first quarter worth $50,000. Hedge funds and other institutional investors own 85.44% of the company’s stock.

In other news, EVP Patrick Kaltenbach sold 1,272 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $260.00, for a total transaction of $330,720.00. Following the transaction, the executive vice president now directly owns 10,340 shares of the company’s stock, valued at $2,688,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.12% of the stock is currently owned by company insiders.

A number of brokerages recently issued reports on BDX. William Blair reiterated an “outperform” rating on shares of Becton Dickinson and in a research report on Thursday, July 2nd. UBS Group increased their price objective on Becton Dickinson and from $260.00 to $265.00 and gave the stock a “neutral” rating in a research report on Friday, May 8th. Stifel Nicolaus increased their price objective on Becton Dickinson and from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. SVB Leerink increased their price objective on Becton Dickinson and from $262.00 to $277.00 and gave the stock a “market perform” rating in a research report on Wednesday, July 15th. Finally, KeyCorp reiterated a “hold” rating on shares of Becton Dickinson and in a research report on Tuesday, May 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $275.06.

Shares of NYSE:BDX traded up $7.50 on Friday, reaching $281.34. 1,491,504 shares of the company traded hands, compared to its average volume of 1,254,232. The business’s 50-day simple moving average is $250.93 and its 200 day simple moving average is $250.95. Becton Dickinson and Co has a 52 week low of $197.75 and a 52 week high of $286.72. The stock has a market capitalization of $76.29 billion, a P/E ratio of 84.74, a price-to-earnings-growth ratio of 3.64 and a beta of 0.93. The company has a current ratio of 0.98, a quick ratio of 0.66 and a debt-to-equity ratio of 0.80.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.32 by $0.23. Becton Dickinson and had a return on equity of 15.75% and a net margin of 6.10%. The firm had revenue of $4.25 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the firm earned $2.59 earnings per share. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. Sell-side analysts expect that Becton Dickinson and Co will post 10.35 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $0.79 per share. The ex-dividend date is Tuesday, September 8th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.12%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.05%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is a closed-end mutual fund (CEF)?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.